Table 1.
Baseline characteristics of the recipients and their donors n (%)
| Group A | Group B | Group C |
P value |
|||
| A <-> B | A <-> C | B <-> C | ||||
| Number of patients | 4684 | 491 | 158 | - | - | - |
| Age, mean ± SD (range) (yr) | 48.2 ± 9.3 (19-76) | 48.3 ± 9.5 (19-73) | 48.4 ± 8 (26-71) | 0.892 | 0.998 | 0.956 |
| Male sex | 4136 (88.3) | 436 (88.8) | 142 (89.9) | 0.744 | 0.544 | 0.707 |
| MELD score at LT, mean ± SD (range) | 18.0 ± 9.5 (6-84) | 17.6 ± 10.1 (6-65) | 16.8 ± 9.2 (6-50) | 0.205 | 0.250 | 0.847 |
| Child-Pugh score at LT, mean ± SD (range) | 8.9 ± 2.5 (5-15) | 8.7 ± 2.8 (5-15) | 8.7 ± 2.7 (5-14) | 0.391 | 0.771 | 0.999 |
| With HCC | 2146 (45.8) | 251 (51.1) | 76 (48.1) | 0.025 | 0.571 | 0.509 |
| Pre-LT HBeAg positivity | 1169 (25.0) | 171 (34.8) | 58 (36.7) | < 0.001 | 0.001 | 0.667 |
| Pre-LT HBV DNA positivity | 2248 (48.0) | 168 (34.2) | 62 (39.2) | < 0.001 | 0.030 | 0.251 |
| HBV DNA ≥ 105 copies/mL at LT | 1024 (21.9) | 40 (8.1) | 17 (10.8) | < 0.001 | 0.001 | 0.313 |
| Pre-LT antiviral therapy | 2604 (55.6) | 272 (55.4) | 104 (65.8) | 0.934 | 0.011 | 0.021 |
| Duration of antiviral therapy before LT, mean ± SD (range) (d) | 233.4 ± 604.4 (1-7633) | 92.8 ± 299.3 (1-3280) | 347.1 ± 899.0 (2-7766) | 0.804 | < 0.001 | < 0.001 |
| Number of donors | 4684 | 491 | 158 | - | - | - |
| Age, mean ± SD (range) (yr) | 28.8 ± 6.2 (18-62) | 29.1 ± 6.9 (19-61) | 29.3 ± 6.3 (20-51) | 0.997 | 0.700 | 0.737 |
| Male sex | 4495 (96.0) | 467 (95.1) | 147 (93.0) | 0.365 | 0.069 | 0.315 |
| Deceased donor | 4373 (93.4) | 424 (86.4) | 129 (81.7) | < 0.001 | < 0.001 | 0.147 |
| Living donor | 311 (6.6) | 67 (13.7) | 29 (18.3) | < 0.001 | < 0.001 | 0.147 |
| BMI, mean ± SD (range) | 22.4 ± 2.7 (15.5-52.1) | 23.2 ± 2.7 (17.6-30.5) | 22.6 ± 2.9 (15.8-28.4) | 0.069 | 0.895 | 0.646 |
| HBsAb positivity | 606 (12.9) | 68 (13.8) | 27 (17.1) | 0.568 | 0.128 | 0.316 |
| HBcAb positivity | 160 (3.4) | 21 (4.3) | 2 (1.3) | 0.323 | 0.139 | 0.075 |
MELD: Model for end-stage liver disease; LT: Liver transplantation; HCC: Hepatocellular carcinoma; HBeAg: Hepatitis B e antigen; HBV DNA: Hepatitis B virus deoxyribonucleic acid; BMI: Body mass index; HBsAb: Hepatitis B surface antibody; HBcAb: Hepatitis B core antibody.